- Patent Title: Combined use of Fc gamma RIIb (CD32B) and CD20-specific antibodies
-
Application No.: US13817744Application Date: 2011-08-19
-
Publication No.: US10525129B2Publication Date: 2020-01-07
- Inventor: Mark Cragg , Martin Glennie , Ali Roghanian , Stephen Beers , Peter Johnson , Sean Lim , Bjorn Frendeus , Ingrid Teige
- Applicant: Mark Cragg , Martin Glennie , Ali Roghanian , Stephen Beers , Peter Johnson , Sean Lim , Bjorn Frendeus , Ingrid Teige
- Applicant Address: GB Southampton
- Assignee: University of Southampton
- Current Assignee: University of Southampton
- Current Assignee Address: GB Southampton
- Agency: Booth Udall Fuller, PLC
- Agent Rodney J. Fuller
- Priority: GB1013989.7 20100820
- International Application: PCT/GB2011/051572 WO 20110819
- International Announcement: WO2012/022985 WO 20120223
- Main IPC: A61K39/395
- IPC: A61K39/395 ; A61K39/40 ; C07K16/28 ; G01N33/68 ; C07K16/00 ; A61K39/00
Abstract:
The invention provides a method of treating a patient having target cells that express FcyRIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding FcyRIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and FcyRIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of FcyRIIb.
Public/Granted literature
- US20130251706A1 COMBINED USE OF FC GAMMA RIIB (CD32B) AND CD20 - SPECIFIC ANTIBODIES Public/Granted day:2013-09-26
Information query
